Product image of Kenacort-A 40 (Triamcinolone Acetonide) supplied by GNH India

Kenacort-A 40

Active Ingredient:
Triamcinolone Acetonide
Origin:
EU

Kenacort-A 40 (Triamcinolone Acetonide)

Triamcinolone Acetonide, the active ingredient in Kenacort-A 40, is a corticosteroid (glucocorticoid) presented as a sterile injectable preparation for intra‑articular, intrabursal and intramuscular use. It is employed to reduce inflammation and pain in various joint and soft‑tissue conditions, particularly in adult patients with inflammatory musculoskeletal disorders.

GNH India supplies Kenacort-A 40 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bristol-Myers Squibb B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Kenacort-A 40 is a glucocorticoid used to manage inflammatory conditions of the musculoskeletal system by direct injection into the affected site.
  • Rheumatoid arthritis: diminishes synovial inflammation and joint pain when injected intra‑articularly.
  • Osteoarthritis: alleviates joint swelling and improves mobility in affected joints.
  • Bursitis: reduces bursal inflammation and discomfort after intrabursal administration.
  • Tendinitis: suppresses tendon sheath inflammation and pain when given intratendinously.
  • Inflammatory joint conditions requiring intra‑articular injection: provides rapid anti‑inflammatory effect to improve function.

How It Works

  • Triamcinolone acetonide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses the production of pro‑inflammatory cytokines, chemokines, and adhesion molecules, while enhancing anti‑inflammatory protein synthesis, leading to reduced cellular infiltration and edema in the injected tissue.

Side Effects

Kenacort‑A 40 may cause a range of adverse reactions following injection.

Common Side Effects

  • Local pain or tenderness at the injection site.
  • Transient swelling or erythema.
  • Mild increase in blood glucose in diabetic patients.
  • Temporary bruising or discoloration.
  • Minor headache.

Serious or Rare Side Effects

  • Joint infection (septic arthritis).
  • Tendon rupture or weakening.
  • Osteonecrosis of the bone.
  • Systemic adrenal suppression with repeated dosing.
  • Allergic reaction including urticaria or anaphylaxis.

Precautions & Warnings

  • Before using Kenacort‑A 40, consider the following safety measures.
  • Avoid use in patients with active infection at the injection site: risk of spreading infection.
  • Monitor blood glucose in diabetic patients: glucocorticoids can raise glucose levels.
  • Limit frequency of injections: repeated use may cause tissue atrophy or systemic effects.
  • Screen for hypersensitivity to corticosteroids: prior allergic reactions increase risk.
  • Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Avoid Interactions

Kenacort‑A 40 can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Systemic corticosteroids: additive immunosuppression and adrenal suppression.
  • Anticoagulants (e.g., warfarin): increased risk of bleeding at injection site.
  • Live vaccines: reduced vaccine efficacy and possible infection.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase local irritation.
  • Diuretics: potential for electrolyte imbalance.
  • Antidiabetic agents: may require dose adjustment due to hyperglycaemia.

Frequently Asked Questions

Kenacort‑A 40 contains triamcinolone acetonide and is used as an injectable corticosteroid to treat inflammatory joint conditions such as rheumatoid arthritis, osteoarthritis, bursitis, and tendinitis by reducing pain and swelling directly at the affected site.

Triamcinolone acetonide binds to glucocorticoid receptors inside cells, altering gene expression to suppress pro‑inflammatory cytokines and promote anti‑inflammatory proteins, which together diminish inflammation and immune activity in the injected tissue.

The dosage and frequency of Kenacort‑A 40 are determined by the prescribing clinician based on the specific condition, joint size, and patient factors. No standard regimen is provided here; the prescriber sets the appropriate dose.

Safety of triamcinolone acetonide during pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Kenacort‑A 40 (triamcinolone acetonide) offers a high‑potency glucocorticoid effect with a relatively long duration of action compared with lower‑potency steroids such as methylprednisolone. Choice of agent depends on clinician preference, required duration, and patient tolerance.

Kenacort‑A 40 should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperatures to maintain sterility and potency.

The product is supplied as a sterile injectable solution and is administered by a qualified healthcare professional via intra‑articular, intrabursal or intramuscular injection, depending on the targeted joint or tissue.

Serious risks include joint infection (septic arthritis), tendon rupture, osteonecrosis, systemic adrenal suppression with repeated dosing, and severe allergic reactions such as anaphylaxis. Patients should be monitored closely for these events.

Kenacort‑A 40 is contraindicated in patients with active infection at the injection site, known hypersensitivity to triamcinolone or other corticosteroids, and in those with uncontrolled systemic infections. It should also be avoided in patients where systemic corticosteroid therapy is contraindicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Triamcinolone Acetonide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT